Romatoid Artrit Hastalarında 128 Haftalık Açık Etiketli, Uzun Dönem Uzatma Çalışmasında Baricitinib’in Güvenliği ve Etkinliği
J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161This open-label extension (OLE) of a Phase 2b randomised controlled trial (RCT) found that safety data collected over 2 years of treatment were generally consistent with previous findings for baricitinib in RA.In the RCT, baricitinib demonstrated significant improvement in disease activity compared with placebo and an acceptable safety profile in patients with RA and an inadequate response to MTX. Patients who completed the 24-week double-blind period of the study were eligible for the OLE. Rate...
Aktif Romatoid Artrit Olguları Faz 2b Çalışmasında Baricitinibin Lipid, Apolipoprotein ve Lipoprotein Partikülleri Üzerine Etkileri
Arthritis Rheumatol 2017. DOI 10.1002/art.40036.In this analysis of the effect of baricitinib on changes in lipid profile, lipoprotein particle size and apolipoprotein content, increases in serum lipids were observed with HDL-C increases correlating with improved clinical outcomes.Eligible patients (N=301) met the inclusion criteria for the Phase 2b randomised, double-blind, placebo-controlled study.1 Patients were assigned in a 2:1:1:1:1 ratio to once-daily doses of placebo or baricitinib 1, 2, 4, or 8 mg, respectively. Those receiving 2 mg,...
Metotreksata yetersiz yanıt veren romatoid artritli hastalarda baricitinibin 24 haftadaki güvenlik ve etkinliği
Ann Rheum Dis. 2015;74(2):333–340Recent innovations in the treatment of RA have focused on the use of small molecules to inhibit intracellular kinases such as the JAK family. Baricitinib (LY3009104, formerly INCB028050) is an orally administered, potent, selective and reversible inhibitor of JAK1 and JAK2, which has shown anti-inflammatory effects, as well as preservation of cartilage and bone, in preclinical rodent studies.
This phase IIb study was designed to investigate multiple doses and dosing regimens of baricitin...